Veranstaltung an
The importance of LF-LAM technology in TB diagnosis among patients with advanced HIV diagnosis
Background
According to the World Health Organization (WHO), in 2017 the risk of developing TB for the 38 million people living with HIV was 18 times higher than the risk for the rest of the global population. In 2019, a total of 456 426 cases of TB were notified among HIV-positive people and about 208 000 deaths from TB were reported in the same population.
In 2019, the WHO Global TB Programme provided updated clinical guidance and management on the use of the LF-LAM assay for the diagnosis of TB in PLHIV. The implementation of LF-LAM in patients with advanced HIV disease has showed promise as a simple, inexpensive POC platform. The webinar serves to provide insight into practical implementation of LF-LAM and demonstrate the successful integration in the South African context.
PRESENTATIONS
-
Dr Kuku Appiah
(South Africa)
ChairpersonWelcome and overview of advanced disease package of care by Abbott Rapid Diagnostics (English)
-
-
Mr David Branigan
(USA)
Speaker -
Mr Zibusiso Ndlovu
(South Africa)
SpeakerScaling-up access to urine TB LAM: MSF experiences (English)
-
Dr Evans Mathebula
(South Africa)
Moderator -
The views and opinions presented are of the author only. The content contained in this webcast is intended for informational / educational purposes only.
© 2022 Abbott. Alle Rechte vorbehalten. Alle genannten Marken sind Marken der Abbott-Unternehmensgruppe oder ihrer jeweiligen Eigentümer. Alle angezeigten Fotos dienen nur zur Veranschaulichung. Jede auf solchen Fotos abgebildete Person ist ein Model. Produkte nur in ausgewählten Märkten erhältlich. COL-10481
